MedTrace Logo

Sarcopenic Index and Related Factors in Patients With Type 2 Diabetes

NCT06539923 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 839

Last updated 2024-08-06

No results posted yet for this study

Summary

Sarcopenia, characterized by a progressive loss of skeletal muscle mass and function, is particularly common in individuals with T2DM and is often associated with insulin resistance, chronic inflammation and oxidative stress. The Sarcopenia Index (SI), calculated as serum creatinine divided by serum cystatin C, is a practical tool for assessing sarcopenia and is used in many clinical settings. In this study, we aimed to investigate the relationship between sarcopenic index and variables such as age, diabetes duration, diabetes control and complication-related parameters such as NT-proBNP and Fib4 score in patients with type 2 diabetes.

Conditions

Interventions

OTHER

retrieving data

Data will be retrieved retrospectively

Sponsors & Collaborators

  • Goztepe Prof Dr Suleyman Yalcın City Hospital

    lead OTHER

Principal Investigators

  • Ayse N Erbakan, MD · Istanbul Medeniyet University

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2024-07-31
Completion
2024-08-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06539923 on ClinicalTrials.gov